DK0485563T3 - Polyethersubstituerede antitumormidler - Google Patents

Polyethersubstituerede antitumormidler

Info

Publication number
DK0485563T3
DK0485563T3 DK91910296.2T DK91910296T DK0485563T3 DK 0485563 T3 DK0485563 T3 DK 0485563T3 DK 91910296 T DK91910296 T DK 91910296T DK 0485563 T3 DK0485563 T3 DK 0485563T3
Authority
DK
Denmark
Prior art keywords
substituted
polyether
amino group
tumor agents
polyethylene glycol
Prior art date
Application number
DK91910296.2T
Other languages
Danish (da)
English (en)
Inventor
Hans-J Sinn
Hans-Hermann Schrenk
Wolfgang Maier-Borst
Eckhard Friedrich
Georgi Graschew
Dieter Woehrle
Thomas Klenner
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4017439A external-priority patent/DE4017439C2/de
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK0485563T3 publication Critical patent/DK0485563T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyethers (AREA)
DK91910296.2T 1990-05-30 1991-05-29 Polyethersubstituerede antitumormidler DK0485563T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4017439A DE4017439C2 (de) 1990-05-30 1990-05-30 Polyethersubstituierte Tumormittel

Publications (1)

Publication Number Publication Date
DK0485563T3 true DK0485563T3 (da) 1995-03-20

Family

ID=6407498

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91910296.2T DK0485563T3 (da) 1990-05-30 1991-05-29 Polyethersubstituerede antitumormidler

Country Status (7)

Country Link
EP (1) EP0485563B1 (fr)
JP (1) JP2640293B2 (fr)
AT (1) ATE115864T1 (fr)
DE (2) DE59103985D1 (fr)
DK (1) DK0485563T3 (fr)
ES (1) ES2068587T3 (fr)
WO (1) WO1991018630A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332952T2 (de) * 1992-09-04 2004-02-19 The General Hospital Corp., Boston Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
ES2140469T3 (es) * 1992-10-14 2000-03-01 Nycomed Imaging As Composiciones y metodos terapeuticos y de diagnostico por obtencion de imagenes.
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
WO1994009056A1 (fr) * 1992-10-14 1994-04-28 Sterling Winthrop Inc. Polymeres de chelation
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
GB9408746D0 (en) * 1994-05-03 1994-06-22 Scotia Holdings Plc Tumour locallising photosensitising compounds
US7255851B2 (en) 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
TW319763B (fr) 1995-02-01 1997-11-11 Epix Medical Inc
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
DE19706490C1 (de) 1997-02-19 1998-09-17 Deutsches Krebsforsch Verfahren zur Herstellung von Säureamiden und zur Metallierung von Verbindungen und Verwendung der nach den Verfahren hergestellten Verbindungen
WO1998048838A1 (fr) * 1997-04-29 1998-11-05 Nycomed Imaging As Composes
EP1107971B1 (fr) 1998-08-28 2004-11-24 Destiny Pharma Limited Derives porphyrine, leur utilisation en therapie photodynamique, et dispositifs medicaux les contenant
GB0005855D0 (en) 2000-03-10 2000-05-03 Scotia Holdings Plc Compounds for pdt
ITPD20030174A1 (it) * 2003-07-31 2003-10-29 Univ Padova Coniugati polimerici per diagnostica e terapia
IL168184A (en) * 2005-04-21 2011-11-30 Univ Ariel Res & Dev Co Ltd Use of a ligand-photosensitizer conjugate in combination with a chemiluminescent agent in the manufacture of a medicament for photodynamic therapy
US8853247B2 (en) 2007-11-02 2014-10-07 Nektar Therapeutics Oligomer-nitroimidazole anti-infective conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
US4830847A (en) * 1985-06-28 1989-05-16 The Procter & Gamble Company Diphosphonate-derivatized macromolecules
IN165717B (fr) * 1986-08-07 1989-12-23 Battelle Memorial Institute
AU611932B2 (en) * 1987-08-21 1991-06-27 Wellcome Foundation Limited, The Novel complex
JPH0751592B2 (ja) * 1987-12-28 1995-06-05 帝人株式会社 シクロトリフォスファゼン誘導体
DE3809671A1 (de) * 1988-03-18 1989-09-28 Schering Ag Porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
JPH0796558B2 (ja) 1988-03-31 1995-10-18 協和醗酵工業株式会社 修飾ポリペプチド
AU5858690A (en) 1989-06-14 1991-01-08 Cetus Corporation Polymer/antibiotic conjugate
DE4017439C2 (de) * 1990-05-30 1994-06-23 Deutsches Krebsforsch Polyethersubstituierte Tumormittel

Also Published As

Publication number Publication date
JP2640293B2 (ja) 1997-08-13
DE59103985D1 (en) 1995-02-02
WO1991018630A1 (fr) 1991-12-12
ES2068587T3 (es) 1995-04-16
EP0485563B1 (fr) 1994-12-21
JPH05501885A (ja) 1993-04-08
EP0485563A1 (fr) 1992-05-20
DE4139715C2 (de) 1994-08-11
ATE115864T1 (de) 1995-01-15
DE4139715A1 (de) 1993-06-03

Similar Documents

Publication Publication Date Title
DK0485563T3 (da) Polyethersubstituerede antitumormidler
ES507033A0 (es) Metodo y aparato para extruir polimeros de etileno lineales de estrecha distribucion de peso molecular.
IT8026950A0 (it) Particelle di sostanze solubili in lipoidi e composizioni biologicamente attive che le contengono.
DE3885317D1 (de) Makromolekulare Platin-Antitumorverbindungen.
ATE355848T1 (de) Verwendung von einem phospatidylserine/polypeptide konjugat um autoimmunität hervorzurufen in der behandlung von krebs
NO166943C (no) Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider.
AR001267A1 (es) Negro de humo tratado método para prepararlo formulación polímerica que lo incluye dispositivo y blindaje que comprenden dicha formulación polímerica
SE7611420L (sv) Hogmolekylera polyaminer och sett for deras framstellning
ATE72116T1 (de) Erhoehung der tetracyclinwirkung.
DE3783242D1 (de) Aminogruppen enthaltende hochmolekulare verbindungen und deren verwendung.
SE7612432L (sv) Komposition och forfarande for dispergering av hogmolekylera flockningspolymerer i vatten
AR222763A1 (es) Composiciones de polimeros para el tratamiento de cueros depilados y de cueros curtidos
FI871983A7 (fi) Perfluoripolyeettereitä, jotka eivät sisällä peroksidihappea ja joiden perfluoripolyeetteriketjussa on perfluoriepoksiryhmiä, sekä niiden johdannaisia.
MX9306960A (es) Composiciones de extracto de corteza de roble, compositiones sinteticasrelacionadas, y metodo para su utilizacion.
FI830075A7 (fi) Polymeerikoostumuksia ja niiden käyttö liima-aineina tai liima- aineissa ja muissa koostumuksissa.
EP0215662A3 (fr) Préparations de protéase antitumorale
ES2088633T3 (es) Estabilizantes polisiloxanicos que contienen grupos fenol y grupos oxamidicos estericamente impedidos.
SE8000466L (sv) Polymeriska immunreglerade medel
ATE146517T1 (de) Öl- und brennölzusammensetzungen
FI830523A0 (fi) Anti-inflammatoriska och/eller smaerta lindrande 2,3-diaryl-5-halotiofener
AT297332B (de) Verfahren zur Molgewichtserhöhung von hochmolekularen linearen Polykondensaten oder von deren Vorprodukten
ES2069543T3 (es) Procedimiento para la obtencion de poliglicoleteres cerrados en los grupos terminales.
ES2128314T3 (es) Nuevos inductores potentes de diferenciacion terminal y metodo de utilizacion de los mismos.
DE59108407D1 (de) Galactomannanderivate zur Umhüllung oder Einbettung von Arzneimittelwirkstoffen
ATE22899T1 (de) Antithrombin-heparin komplex.